Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Heart Failure III: Clinical Manifestations

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...

Heart Failure VII: Nursing Interventions

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Combination Therapy with Bisoprolol and Tissue Protective Molecule ARA 284 Is Cardio-Protective and Improves Survival in Experimental Cancer Cachexia.

Journal of cardiovascular development and disease·2026

Same author

How to query administrative databases for heart failure epidemiological investigations? Rationale, design, and case definition criteria for the nation-wide HF-EPI-HUN Study.

European journal of heart failure·2026

Same author

Translation, cultural adaptation and psychometric evaluation of the Slovene version of the Heart Failure-Specific Health Literacy Scale in patients with heart failure.

Scientific reports·2026

Same author

Combined Bisoprolol and Megestrol Acetate Improves Survival and Preserves Cardiac Performance in a Rat Model of Cancer Cachexia.

Journal of cachexia, sarcopenia and muscle·2026

Same author

Does the global prevalence of heart failure now exceed 600 million people? From guesswork to evidence.

European heart journal·2026

Same author

The Global Epidemiology of Heart Failure: A Comprehensive and Contemporary Review.

European journal of heart failure·2026

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Biomarkers for chronic heart failure.

Mitja Lainscak¹, Stephan von Haehling, Jochen Springer

¹Division of Applied Cachexia Research, Department of Cardiology, Campus Virchow Clinic, Charité - Universitätsmedizin Berlin, Berlin, Germany. mitja.lainscak@guest.arnes.si

Heart Failure Monitor

|May 10, 2007

Summary

Current heart failure biomarkers like natriuretic peptides are useful but insufficient. This review explores novel biomarkers such as hemoglobin and cholesterol for improved chronic heart failure management.

Related Experiment Videos

Last Updated: Jul 15, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Area of Science:

Cardiology
Biomarker Discovery
Chronic Disease Management

Background:

Cardiac biomarkers are crucial for understanding and managing chronic heart failure (CHF).
Natriuretic peptides, including B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP), aid in CHF diagnosis and prognosis.
Existing biomarkers do not fully meet the criteria for an ideal diagnostic and prognostic tool in CHF.

Purpose of the Study:

To review current cardiac biomarkers for chronic heart failure (CHF).
To explore the potential of underutilized biomarkers in CHF.
To discuss the synergistic role of combining multiple biomarkers for comprehensive CHF assessment.

Main Methods:

Literature review of existing and emerging cardiac biomarkers.
Analysis of pathophysiological relevance of various biomarkers in CHF.
Speculative discussion on the combined utility of multiple biomarkers.

Main Results:

Natriuretic peptides (BNP, NT-proBNP) are established but limited in CHF assessment.
Hemoglobin, cholesterol, and uric acid are identified as potentially valuable biomarkers.
Emerging proteins show promise for CHF evaluation.

Conclusions:

No single biomarker currently suffices for all clinical questions in CHF.
Combining established and novel biomarkers may offer a more complete pathophysiological understanding and improved clinical utility.
Further research into combined biomarker panels is warranted for advancing CHF care and managing related chronic diseases.